据香港交易所披露，贝莱德（BlackRock）对无锡药明康德新药开发股份有限公司 - H股的多头持仓比例 于2025年12月23日从5.1%降至4.72%。 ...

Core Viewpoint - The precision medicine sector experienced a slight increase of 0.18% on December 26, with WuXi AppTec leading the gains [1] Market Performance - The Shanghai Composite Index closed at 3963.68, up by 0.1% - The Shenzhen Component Index closed at 13603.89, up by 0.54% [1] Fund Flow Analysis - The precision medicine sector saw a net outflow of 278 million yuan from major funds - Retail investors contributed a net inflow of 259 million yuan - Speculative funds recorded a net inflow of 18.61 million yuan [1]

Core Viewpoint - The strong growth of WuXi AppTec's performance is attributed to its accelerating globalization strategy, which is becoming a key differentiator for long-term competitiveness in the pharmaceutical industry [1] Group 1: Company Performance - For the first three quarters of 2025, WuXi AppTec achieved revenue of 32.86 billion yuan, a year-on-year increase of 18.6%, and a net profit attributable to shareholders of 12.076 billion yuan, significantly up by 84.8% [1] - The company's performance is not merely a result of cyclical rebound but reflects the amplification of its globalization capabilities in a complex environment [1] Group 2: Globalization Strategy - WuXi AppTec's globalization is a systematic project involving the establishment of global production capacity, expansion of cross-regional R&D networks, and further internationalization of its customer base [1] - The company is evolving into a platform enterprise that plays a foundational role in the global innovative drug ecosystem [1] Group 3: Marginal Effects of Globalization - The marginal effects of global production capacity are becoming evident, with significant improvements in service capabilities in advanced technology areas such as complex molecules, TIDES, and peptides [2] - TIDES business revenue grew by 121.1% year-on-year in the first three quarters of 2025, driven by the synergy of production capacity, technology, and global delivery systems [2] Group 4: Order Quality and Market Position - As of September 30, 2025, the company's backlog of orders reached 59.88 billion yuan, a year-on-year increase of 41.2%, indicating a strong order quality that is expected to provide stable future revenue [2] - The quality of orders reflects the genuine recognition of the company's capabilities by the global innovative drug industry, independent of market fluctuations [2] Group 5: Industry Outlook - The global pharmaceutical R&D outsourcing market is on a structurally growing trajectory, with increasing outsourcing penetration due to rising R&D costs and compressed innovation cycles [3] - WuXi AppTec's strategic accumulation in global layout, technical depth, talent systems, and operational efficiency positions it well to capture the growth dividends of global innovative drugs [3] Group 6: Future Growth Confidence - The company has raised its revenue growth forecast for 2025 to 17-18%, reflecting confidence derived from its globalization framework, continuous capacity release, deepening customer ties, and strong order backlog [3] - This growth is seen as a natural outcome of deepening globalization rather than a temporary rebound driven by industry cycles [3]

Core Viewpoint - The global biopharmaceutical investment and financing activities are showing signs of recovery, with the CXO industry in China experiencing improved sentiment, despite concerns over major shareholders' share reduction actions [1] Group 1: Shareholder Actions - WuXi AppTec announced that 17 shareholders plan to reduce their holdings by up to 59.675 million shares, or 2% of the total share capital, starting from November 20, 2025 [1] - Previous reductions by WuXi AppTec in April and August 2023 led to significant short-term stock price declines, coinciding with a broader market correction in the innovative drug sector, which saw a nearly 20% drop in the innovation drug index [2][4] Group 2: Market Reactions - Despite liquidity concerns from major shareholder reductions, WuXi AppTec's stock price did not significantly decline, indicating rational market judgment regarding the company's fundamentals [4] - The number of shareholders increased from 281,200 at the end of March 2023 to 301,400 by the end of June 2023, suggesting that informed investors took advantage of price dips to lower their average cost [4] Group 3: Financial Performance and Returns - WuXi AppTec's stock price has recovered strongly since the reduction announcements, with a cumulative increase of over 140% [4] - The company announced its first interim dividend of 1.03 billion yuan, representing 21.1% of the total annual cash dividend, following a substantial total dividend of 2.835 billion yuan for 2024 [5] - The company has completed share buybacks totaling 20 billion yuan, which have been used for cancellation, effectively increasing earnings per share (EPS) and enhancing shareholder value [5] Group 4: Governance and Investment Strategy - The reduction in major shareholders' stakes has not compromised the actual control of the company, maintaining strategic decision-making authority [6] - Investors are encouraged to differentiate the nature of share reductions and assess the company's fundamentals, as strong fundamentals and reasonable valuations can create opportunities for investment at attractive prices [6]

沪指12月22日上涨0.69%，申万所属行业中，今日上涨的有22个，涨幅居前的行业为通信、综合，涨幅 分别为4.28%、2.63%。跌幅居前的行业为传媒、银行，跌幅分别为0.61%、0.52%。医药生物行业今日 下跌0.22%。 资金面上看，两市主力资金全天净流入66.05亿元，今日有11个行业主力资金净流入，通信行业主力资 金净流入规模居首，该行业今日上涨4.28%，全天净流入资金75.16亿元，其次是电子行业，日涨幅为 2.62%，净流入资金为60.73亿元。 主力资金净流出的行业有20个，计算机行业主力资金净流出规模居首，全天净流出资金24.08亿元，其 次是传媒行业，净流出资金为22.63亿元，净流出资金较多的还有医药生物、商贸零售、机械设备等行 业。 医药生物行业今日下跌0.22%，全天主力资金净流出17.07亿元，该行业所属的个股共478只，今日上涨 的有152只，涨停的有6只；下跌的有310只，跌停的有1只。以资金流向数据进行统计，该行业资金净流 入的个股有176只，其中，净流入资金超3000万元的有10只，净流入资金居首的是康芝药业，今日净流 入资金3.21亿元，紧随其后的是海南海药、新诺威， ...

格隆汇12月22日｜港交所文件显示，贝莱德在药明康德(2359.HK)H股多头持仓比例于12月17日从4.65% 增至5.10%。 ...

Core Viewpoint - The unusual phenomenon of 18 shareholders collectively reducing their stakes in WuXi AppTec (603259.SH) raises market concerns, as these shareholders are associated with the company's actual controller, Ge Li [1][2][5]. Group 1: Shareholder Reduction - From November 26 to December 17, 18 shareholders reduced their holdings by a total of 29.51 million shares, representing 0.989% of the company's total share capital on the announcement date [1][5]. - Cumulatively, these shareholders have reduced approximately 41.34 million shares, resulting in a cash-out of around 3.8 billion yuan [1][6]. - The actual controller and related parties have previously engaged in significant cash-outs, totaling over 10.28 billion yuan since the company's IPO [8][9]. Group 2: Financial Performance - In 2025, WuXi AppTec's revenue and net profit saw substantial growth, with a net profit exceeding 12 billion yuan in the first three quarters, marking an over 80% year-on-year increase [3][11]. - Despite the impressive financial performance, the company's R&D investment has decreased, with a 13.42% reduction in the first three quarters of 2025 compared to the previous year [4][15]. - The company reported a significant increase in investment income, primarily due to the sale of shares in WuXi AppTec's subsidiary, contributing approximately 4.35 billion yuan to the net profit for 2025 [14].

两融数据显示，该股最新融资余额为72.39亿元，近5日增加282.01万元，增幅为0.04%。（数据宝） 12月19日药明康德大宗交易一览 药明康德12月19日大宗交易平台共发生10笔成交，合计成交量300.00万股，成交金额2.64亿元。成交价 格均为87.85元，相对今日收盘价折价5.00%。从参与大宗交易营业部来看，机构专用席位共出现在5笔 成交的买方或卖方营业部中，合计成交金额为2.00亿元，净买入2.00亿元。 进一步统计，近3个月内该股累计发生42笔大宗交易，合计成交金额为16.91亿元。 证券时报·数据宝统计显示，药明康德今日收盘价为92.47元，上涨2.08%，日换手率为1.88%，成交额为 43.16亿元，全天主力资金净流入4.02亿元，近5日该股累计下跌1.68%，近5日资金合计净流入1.25亿 元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 78.96 | ...

Investment Overview - The company, WuXi AppTec Healthcare Holding S.C.S.p, has signed a Subscription Agreement to invest €10 million (approximately ¥82.76 million) in the Jeito II S.L.P. private equity fund, representing 1.07% of the fund's total raised shares [2][4] - After the completion of the Subscription Agreement and Transfer Agreement, WuXi Lux Holding will hold a total of €30 million in A-class shares, accounting for approximately 3.22% of the total raised fund [3][8] - This investment does not require approval from the company's board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring as defined by regulations [2][3] Fund Management and Structure - The investment fund is established under French law, targeting innovative companies in the biopharmaceutical sector with significant clinical needs and commercialization potential [8][15] - The fund's total size is capped at €1.2 billion, with approximately €931 million raised to date [8] - The fund's management team, Jeito Capital S.A.S., is noted for its professional investment management capabilities and compliance with local laws [4][6] Investment Strategy and Goals - The fund aims to invest in 14 to 17 early-stage medical innovation startups, focusing on biopharmaceutical companies [15][16] - The expected return model is based on asset appreciation after deducting management fees [16] - The fund will enter a liquidation phase at the end of its term, with a structured process for asset realization and distribution to investors [17] Impact on the Company - The investment is expected to enhance the company's understanding of developments in the European biopharmaceutical sector, which is a key potential customer base [19] - The company believes that the management team's experience and resources will provide critical growth capital and operational guidance to European biopharmaceutical startups [19] - The investment will not significantly impact the company's financial status or operational results, as it is made with the company's own funds while ensuring sufficient capital for daily operations [19]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月19日，药明康德收涨2.08%，收盘价为92.47元，发生10笔大宗交易，合计成交量300万股，成交金 额2.64亿元。 第1笔成交价格为87.85元，成交78.96万股，成交金额6,936.74万元，溢价率为-5.00%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司上海分公司。 第6笔成交价格为87.85元，成交19.95万股，成交金额1,752.63万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第7笔成交价格为87.85元，成交16.49万股，成交金额1,448.31万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第8笔成交价格为87.85元，成交6.23万股，成交金额547.49万元，溢价率为-5.00%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第9笔成交价格为87.85元，成 ...